| Title |
CT-P13: design, development, and place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2017
|
| DOI | 10.2147/dddt.s109852 |
| Pubmed ID | |
| Authors |
Tommaso Gabbani, Simona Deiana, Vito Annese |
| Abstract |
The introduction of biological agents has revolutionized the management of many life-threatening and debilitating immune-mediated diseases. Because of the high cost of biological drugs and their patent expiration, the market has opened to biosimilar agents, copy versions of the originators, which can lead to reduced health care expenditure and increase treatment access worldwide. CT-P13 is the first biosimilar of infliximab (IFX) and has been approved for the same indications as its originator drug. It obtained regulatory approval by the European Medicines Agency in September 2013 and by the US Food and Drug Administration in April 2016. The Phase I and Phase III clinical trials conducted in ankylosing spondylitis and rheumatoid arthritis have demonstrated pharmacokinetic and efficacy equivalence with comparable safety and immunogenicity to IFX. For these reasons, the use of CT-P13 has been extrapolated also to inflammatory bowel disease. There have been some initial concerns regarding the use of CT-P13 in inflammatory bowel disease patients, because of the lack of randomized controlled trials. However, emerging real-world data have further confirmed the comparability between CT-P13 and its reference product in terms of efficacy, safety, and immunogenicity, in patients naïve to the anti-tumor necrosis factor alpha agents and after switching from IFX, and will be summarized in this review. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 14% |
| Student > Ph. D. Student | 14 | 12% |
| Researcher | 14 | 12% |
| Student > Master | 13 | 11% |
| Other | 6 | 5% |
| Other | 20 | 17% |
| Unknown | 33 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 16% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Nursing and Health Professions | 4 | 3% |
| Computer Science | 3 | 3% |
| Other | 12 | 10% |
| Unknown | 38 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2019.
All research outputs
#4,674,359
of 25,604,262 outputs
Outputs from Drug Design, Development and Therapy
#282
of 2,271 outputs
Outputs of similar age
#75,677
of 331,069 outputs
Outputs of similar age from Drug Design, Development and Therapy
#7
of 44 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.